U.S. markets open in 4 hours 2 minutes

Strategic Asset Leasing Inc. (LEAS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0010+0.0000 (+5.00%)
At close: 02:04PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0010
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0010 - 0.0011
52 Week Range0.0005 - 0.0188
Avg. Volume12,622,527
Market Cap874,999
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for LEAS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    SRCL: Lowering target price to $33.00STERICYCLE INC has an Investment Rating of SELL; a target price of $33.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Newsfile

    ANEW MEDICAL, INC. to Present at the Investor Summit Group's Q2 In-Person Conference

    New York, New York--(Newsfile Corp. - April 29, 2022) - ANEW MEDICAL, INC., (OTC Pink: LEAS) today announced that Dr. Joseph Sinkule, the CEO and Founder of ANEW MEDICAL INC. (ANEW), will be attending and presenting at The Q2 Investor Summit Group - In-Person. ANEW is focused on completing a late-stage, randomized Phase 3 study of a biosimilar antibody called bevacizumab (Genentech/Roche Avastin™) and early-stage trials of a cutting-edge genetic therapy targeting neurodegenerative diseases ...

  • GlobeNewswire

    CEO Presenting on the Emerging Growth Conference on March 30 Register Now

    Niche Companies in Ultra Technology, Biotechnology, Fintech, Clean Energy, Oil & Gas, and more in attendanceMIAMI, March 29, 2022 (GLOBE NEWSWIRE) -- a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 28th Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams,